Glycemic Control by Treatment Modalities: National Registry-Based Population Data in Children and Adolescents with Type 1 Diabetes
Authors' conclusion
This population-based study shows that the HCL technology is superior to other treatment modalities in CGM-derived parameters and should be considered as a treatment of choice in all CwD fulfilling the indication criteria.
Study context
- Population
- Children and adolescents <19 years with T1D duration >1 year; mean age 13.4 ± 3.8 yearsanalysed
- Participants
- 3,251 children
- Exposure
- Treatment and monitoring modalities: Multiple daily injection (MDI), CSII, hybrid closed-loop (HCL), by CGM type
- HCLn = 585
- MDIn = 2,187
- Outcome
- Key parameters of T1D control: HbA1c, times in glycemic ranges and glucose risk index (GRI)
Methodological detailspopulation-wide pediatric diabetes registry ČENDA
- Population-wide pediatric diabetes registry ČENDA
Main finding
As reported in the abstract
| Group | Value | Glucose risk index (GRI) |
|---|---|---|
| HCL | median 75.4% (IQR 6.3) | 29.1 (7.8) |
| MDI real-time CGM (rtCGM) | median 68.8% (IQR 9.0) | 38.8 (12.5) |
| CSII | median 69.0% (IQR 7.5) | 40.1 (8.5) |
Value
HCLmedian 75.4% (IQR 6.3)
MDI real-time CGM (rtCGM)median 68.8% (IQR 9.0)
CSIImedian 69.0% (IQR 7.5)
Glucose risk index (GRI)
HCL29.1 (7.8)
MDI real-time CGM (rtCGM)38.8 (12.5)
CSII40.1 (8.5)
- HCL vs other groups: P < 0.001 — highest TIR and lowest GRI with HCL
- MDI rtCGM vs CSII: nonsignificant to each other — nonsignificant to each other
Observational data: associations, not effects.
Further findings
HbA1c
HbA1c
- These three groups did not significantly differ in HbA1c medians
Original publication
Glycemic Control by Treatment Modalities: National Registry-Based Population Data in Children and Adolescents with Type 1 Diabetes. Horm Res Paediatr. Published 26 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →